David Rizzieri, MD

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, David Rizzieri, MD sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 7 completed early-phase tilt upper quartile by trial count

David Rizzieri, MD: 8 sponsored US clinical trials, none currently recruiting.

David Rizzieri, MD sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myelodysplasia, with 3 trials.

Upper-quartile sponsor footprint

David Rizzieri, MD sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 1

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

NCT01373229
COMPLETED Phase 2

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

NCT00597714
TERMINATED Phase 2

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

NCT00511043
COMPLETED Phase 2

Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath

NCT00578942
COMPLETED Phase 1

Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT

NCT00586690
COMPLETED Phase 1

Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT

NCT00586703
COMPLETED Phase 2

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

NCT00580034
COMPLETED Phase 2

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

NCT00004143

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 5

Therapeutic Areas

Myelodysplasia 3
Myeloma 3
Leukemia 3
Solid Tumors 2
Lymphoma 2
Hodgkin's Disease 1
Non-Hodgkin's Lymphoma 1

How the David Rizzieri, MD early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 7 completed (88%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Myelodysplasia (3 trials), 6 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

David Rizzieri, MD: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

David Rizzieri, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share David Rizzieri, MDAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
David Rizzieri, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

David Rizzieri, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this David Rizzieri, MD page

8 registered trials is a research-attention snapshot, not an endorsement of David Rizzieri, MD or any single study.

  • None of David Rizzieri, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Myelodysplasia is the condition David Rizzieri, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myelodysplasia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. David Rizzieri, MD pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.